- Details
- Philip Koo, Oliver Sartor, and Neal Shore discuss the revolutionary impact of PSMA PET in the detection and management of prostate cancer. The experts explain the approved indications of PSMA PET agents PSMA 11 and PYLARIFY, emphasizing their transformative role in managing high-risk and intermediate-risk prostate cancer patients. Drs. Shore and Sartor detail how these imaging technologies inform...
|
- Details
- Alicia Morgans and Tanya Dorff, discuss the updates to the NCCN guidelines since the approval of PSMA PET CT molecular imaging agents. They discuss new guidance based on the FDA-approved indications in the labels for the use of molecular imaging agents for detecting prostate cancer when PSA levels are still relatively low and when PSA levels are rising. Biographies: Tanya B. Dorff, MD., is an asso...
|
- Details
- In this Society of Nuclear Medicine and Molecular Imaging- Special Session during the 2021 LUGPA CME presentations, Dr Steven Rowe discusses a number of different scenarios that we might encounter clinically where conventional imaging is clearly being replaced by PSMA based imaging. In the last part of his talk, Dr. Rowe focuses on some future directions where PSMA PET may have some interesting th...
|
- Details
- In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Jeremie Calais presents on understanding the physiological PSMA biodistribution and the pathological uptake of the use of PSMA for prostate cancer. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Jeremie Calais, MD, MSc, Director, Clinical Research Pro...
|
- Details
- Alicia Morgans speaks with Jeremie Calais about the evolving landscape of theranostic and imaging modalities in prostate cancer. The discussion primarily focuses on the role of PSMA PET imaging in patient selection for PSMA-directed therapies like lutetium PSMA. Dr. Calais elaborates on the criteria used in the VISION trial and the complexities surrounding the necessity of targeted imaging for tar...
|
- Details
- In a conversation hosted by Phillip Koo, Sam Mehr outlines the intricacies of establishing a theranostics program within a medical oncology practice. Dr. Mehr discusses the "NCS/Nebraska Cancer Specialists model," which aims to offer targeted nuclear therapy through a patient-centered approach. He emphasizes the importance of a multidisciplinary team, including a program director who serves as the...
|
- Details
- In this presentation from Esther Mena Gonzalez, she discusses her team’s findings on the role of castration status or hormone-sensitive castrate-resistance data and androgen deprivation therapy (ADT) in the use of 18F DCFPyL PET/CT. She discussed the objective of her study to be to investigate the performance of 18F DCFPyL in her cohort of patients with documented metastatic prostate cancer who we...
|
- Details
- Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render PSMA i...
|
- Details
- Detection and Localization of Prostate Cancer: Case-based Scan Reading Review PSMA Molecular Targeted Radiation Therapy - Part Three of Three- Scan Reader Training and Discussions Presenter: Andrei Iagaru. Independent Medical Education Initiative Supported by Novartis Pharmaceutical Corporation Biographies: Program Presenter: Andrei H. Iagaru, MD, FACNM, Professor of Radiology - Nuclear Medicine,...
|
- Details
- In this patient-focused educational video, Ephraim Parent shares knowledge with patients on the role of skeletal imaging in prostate cancer. Dr. Parent covers the common ways imaging sans are done and, importantly how your physician applies this information to the treatment of metastatic prostate cancer. This video is provided by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Prosta...
|
